Cargando…
Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy
Spinal muscular atrophy (SMA) is a neurodegenerative disease primarily characterized by a loss of spinal motor neurons, leading to progressive paralysis and premature death in the most severe cases. SMA is caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene, leading to low level...
Autores principales: | Shorrock, Hannah K., Gillingwater, Thomas H., Groen, Ewout J. N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829132/ https://www.ncbi.nlm.nih.gov/pubmed/29380287 http://dx.doi.org/10.1007/s40265-018-0868-8 |
Ejemplares similares
-
Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy
por: Groen, Ewout J N, et al.
Publicado: (2018) -
Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy
por: Hunter, Gillian, et al.
Publicado: (2016) -
UBA1/GARS-dependent pathways drive sensory-motor connectivity defects in spinal muscular atrophy
por: Shorrock, Hannah K, et al.
Publicado: (2018) -
In Vivo Translatome Profiling in Spinal Muscular Atrophy Reveals a Role for SMN Protein in Ribosome Biology
por: Bernabò, Paola, et al.
Publicado: (2017) -
Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA)
por: Šoltić, Darija, et al.
Publicado: (2018)